The membrane complement regulatory protein CD59 promotes tumor growth and predicts poor prognosis in breast cancer

International Journal of Oncology

Volumn 48, Issue 5, 2016, Pages 2015-2024

  Ouyang, Qianwen ^a,b,c,d   Zhang, Long ^b,c   Jiang, Yizhou ^b,c   Ni, Xiaojian ^b,c   Chen, Sheng ^b,c   Ye, Fugui ^e   Du, Yiqun ^b,c   Huang, Liang ^b,c   Ding, Peipei ^b,c   Wang, Na ^b   Yang, Chaoqun ^f   Huang, Tianbao ^g   Sun, Yujing ^b   Li, Shan ^b,c   Xia, Yun ^a   Hu, Weiguo ^b,c   Luo, Rongcheng ^d   Shao, Zhiming ^b,c  

^a The Third Hospital of Nanchang   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c FUDAN UNIVERSITY   (China)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

^e FUJIAN MEDICAL UNIVERSITY   (China)

^f FUDAN UNIVERSITY   (China)

^g TONGJI UNIVERSITY   (China)

Author keywords

Breast cancer; CD59; MDA MB 231 HM; Poor prognosis; Tumor growth

Indexed keywords

BIOLOGICAL MARKER; CD59 ANTIGEN; CD59 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECONDARY; TUMOR CELL LINE;

ADULT; ANIMALS; ANTIGENS, CD59; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MICE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PROGNOSIS; UP-REGULATION;

EID: 84962564833     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3408     Document Type: Article

References (33)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Elmore JG, Armstrong K, Lehman CD and Fletcher SW: Screening for breast cancer. JAMA 293: 1245-1256, 2005.
3. Tabár L, Vitak B, Chen HH, Duffy SW, Yen MF, Chiang CF, Krusemo UB, Tot T and Smith RA: The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am 38: 625-651, 2000.
4. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA and Coebergh JW: An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 107: 309-330, 2008.
5. Foulkes WD, Reis-Filho JS and Narod SA: Tumor size and survival in breast cancer-A reappraisal. Nat Rev Clin Oncol 7: 348-353, 2010.
6. Anan K, Mitsuyama S, Koga K, Tanabe R, Saimura M, Tanabe Y, Watanabe M, Suehara N, Matsunaga H, Nishihara K, et al: Disparities in the survival improvement of recurrent breast cancer. Breast Cancer 17: 48-55, 2010.
7. Nguyen DX, Bos PD and Massagué J: Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284, 2009.
8. Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science 331: 1559-1564, 2011.
9. Morgan BP, Marchbank KJ, Longhi MP, Harris CL and Gallimore AM: Complement: Central to innate immunity and bridging to adaptive responses. Immunol Lett 97: 171-179, 2005.
10. Ricklin D, Hajishengallis G, Yang K and Lambris JD: Complement: A key system for immune surveillance and homeostasis. Nat Immunol 11: 785-797, 2010.
11. Matsumoto M, Takeda J, Inoue N, Hara T, Hatanaka M, Takahashi K, Nagasawa S, Akedo H and Seya T: A novel protein that participates in nonself discrimination of malignant cells by homologous complement. Nat Med 3: 1266-1270, 1997.
12. Dunkelberger JR and Song WC: Complement and its role in innate and adaptive immune responses. Cell Res 20: 34-50, 2010.
13. Zhou X, Hu W and Qin X: The role of complement in the mechanism of action of rituximab for B-cell lymphoma: Implications for therapy. Oncologist 13: 954-966, 2008.
14. Fishelson Z, Donin N, Zell S, Schultz S and Kirschfink M: Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40: 109-123, 2003.
15. Davies A and Lachmann PJ: Membrane defence against complement lysis: The structure and biological properties of CD59. Immunol Res 12: 258-275, 1993.
16. Li B, Lin H, Fan J, Lan J, Zhong Y, Yang Y, Li H and Wang Z: CD59 is overexpressed in human lung cancer and regulates apoptosis of human lung cancer cells. Int J Oncol 43: 850-858, 2013.
17. Hu W, Ge X, You T, Xu T, Zhang J, Wu G, Peng Z, Chorev M, Aktas BH, Halperin JA, et al: Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res 71: 2298-2307, 2011.
18. Rus HG, Niculescu FI and Shin ML: Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev 180: 49-55, 2001.
19. Madjd Z, Pinder SE, Paish C, Ellis IO, Carmichael J and Durrant LG: Loss of CD59 expression in breast tumours correlates with poor survival. J Pathol 200: 633-639, 2003.
20. Li B, Chu X, Gao M and Xu Y: The effects of CD59 gene as a target gene on breast cancer cells. Cell Immunol 272: 61-70, 2011.
21. Terp MG, Lund RR, Jensen ON, Leth-Larsen R and Ditzel HJ: Identification of markers associated with highly aggressive metastatic phenotypes using quantitative comparative proteomics. Cancer Genomics Proteomics 9: 265-273, 2012.
22. Maio M, Brasoveanu LI, Coral S, Sigalotti L, Lamaj E, Gasparollo A, Visintin A, Altomonte M and Fonsatti E: Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review). Int J Oncol 13: 305-318, 1998.
23. Liu ZB, Hou YF, Min-Dong, Di GH, Wu J, Shen ZZ and Shao ZM: PA-MSHA inhibits proliferation and induces apoptosis through the up-regulation and activation of caspases in the human breast cancer cell lines. J Cell Biochem 108: 195-206, 2009.
24. Du Y, Teng X, Wang N, Zhang X, Chen J, Ding P, Qiao Q, Wang Q, Zhang L, Yang C, et al: NF-κB and enhancer-binding CREB protein scaffolded by CREB-binding protein (CBP)/p300 proteins regulate CD59 protein expression to protect cells from complement attack. J Biol Chem 289: 2711-2724, 2014.
25. Detre S, Saclani Jotti G and Dowsett M: A 'quickscore' method for immunohistochemical semiquantitation: Validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48: 876-878, 1995.
26. Harvey JM, Clark GM, Osborne CK and Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481, 1999.
27. Du K and Montminy M: CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 273: 32377-32379, 1998.
28. Choi YH, Lee SN, Aoyagi H, Yamasaki Y, Yoo JY, Park B, Shin DM, Yoon HG and Yoon JH: The extracellular signal-regulated kinase mitogen-activated protein kinase/ribosomal S6 protein kinase 1 cascade phosphorylates cAMP response element-binding protein to induce MUC5B gene expression via D-prostanoid receptor signaling. J Biol Chem 286: 34199-34214, 2011.
29. Boulware MI, Weick JP, Becklund BR, Kuo SP, Groth RD and Mermelstein PG: Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. J Neurosci 25: 5066-5078, 2005.
30. Liu M, Yang YJ, Zheng H, Zhong XR, Wang Y, Wang Z, Wang YG and Wang YP: Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: A retrospective study. Oncol Rep 32: 2619-2627, 2014.
31. Mamidi S, Cinci M, Hasmann M, Fehring V and Kirschfink M: Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab. Mol Oncol 7: 580-594, 2013.
32. Samatar AA and Poulikakos PI: Targeting RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug Discov 13: 928-942, 2014.
33. Lipp AM, Juhasz K, Paar C, Ogris C, Eckerstorfer P, Thuenauer R, Hesse J, Nimmervoll B, Stockinger H, Schütz GJ, et al: Lck mediates signal transmission from CD59 to the TCR/CD3 pathway in Jurkat T cells. PLoS One 9: e85934, 2014.